Announcement: New Pancreatic Cancer Drug Daraxonrasib Shows Promise in Phase 2 Trial

Last updated: 09/06/2026 22:07

0 Min Read

A phase 2 trial published in NEJM shows promise for daraxonrasib, a novel targeted therapy for previously treated metastatic pancreatic cancer. The study compared the new drug to standard chemotherapy in this challenging patient population. — Photo: Tara Winstead / Pexels

1 min read|43 words

Breaking: New targeted therapy daraxonrasib shows promise for metastatic pancreatic cancer in phase 2 trial published in NEJM. Study compared the novel drug to standard chemotherapy in previously treated patients. Important step forward for this challenging disease.

Read the full article on GMJ Newsroom →

Was this article helpful?

GMJ Brief · Announcement

📰 Read the full article: New Pancreatic Cancer Drug Daraxonrasib Shows Promise in Phase 2 Trial →

Share This Article

ByProf. Giorgi Pkhakadze

Follow:

Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Announcement: New Pancreatic Cancer Drug Daraxonrasib Shows Promise in Phase 2 Trial

Submit Your Paper →

Teclistamab Shows Strong Response Rates in Earlier-Line Multiple Myeloma Treatment

E-cigarettes deliberately designed to target youth through availability and addictive features, researchers warn

FDA’s Pazdur Calls for Agency Restructuring Amid China Competition and Internal Upheaval

Submit Your Paper to GMJ

Company

You Might Also Like